Restraining small extracellular vesicles: Dawn of a new era in nanomedicine

Ming Yang; Lin-Zhu Zhang; Hai-Dong Zhu

doi:10.1002/mba2.70006

MEDCOMM - Biomaterials and Applications ›› 2025, Vol. 4 ›› Issue (1) :e70006 DOI: 10.1002/mba2.70006

HIGHLIGHT

Restraining small extracellular vesicles: Dawn of a new era in nanomedicine

Author information +

History +

PDF

Cite this article

Download citation ▾

Ming Yang, Lin-Zhu Zhang, Hai-Dong Zhu. Restraining small extracellular vesicles: Dawn of a new era in nanomedicine. MEDCOMM - Biomaterials and Applications, 2025, 4(1): e70006 DOI:10.1002/mba2.70006

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	GongN, ZhongW, AlamehMG, et al. Tumour-derived small extracellular vesicles act as a barrier to therapeutic nanoparticle delivery. Nat Mater. 2024;23:1736-1747.

[2]	FanD, CaoY, CaoM, WangY, CaoY, GongT. Nanomedicine in cancer therapy. Signal Transduct Target Ther. 2023;8(1):293.

[3]	MitchellMJ, Billingsley MM, HaleyRM, WechslerME, PeppasNA, LangerR. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discovery. 2021;20(2):101-124.

[4]	ZhangC, QinC, DewanjeeS, et al. Tumor-derived small extracellular vesicles in cancer invasion and metastasis: molecular mechanisms, and clinical significance. Mol Cancer. 2024;23(1):18.

[5]	DaassiD, Mahoney KM, FreemanGJ. The importance of exosomal PDL1 in tumour immune evasion. Nat Rev Immunol. 2020;20(4):209-215.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm - Biomaterials and Applications published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).